CHICAGO--(BUSINESS WIRE)--Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) today announced that it held an investigator meeting yesterday at the Interscience Conference on Antimicrobial Agents and Chemotherapy in Chicago. The meeting included a review of the ongoing Phase II clinical study underway, a review of potential trial design and plans for the Phase III trials.
